{"id":"nirmatrelvir-and-ritonavir-stage-1","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Dysgeusia (taste disturbance)"},{"rate":"3-8","effect":"Diarrhea"},{"rate":"2-5","effect":"Nausea"},{"rate":"2-4","effect":"Headache"},{"rate":"1-3","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nirmatrelvir is a protease inhibitor that binds to and blocks the 3CL protease (main protease) of SARS-CoV-2, preventing the cleavage of viral polyproteins necessary for viral replication. Ritonavir, a CYP3A4 inhibitor, is co-administered as a pharmacokinetic booster to increase nirmatrelvir plasma concentrations and extend its half-life, allowing for lower and more practical dosing.","oneSentence":"Nirmatrelvir inhibits the SARS-CoV-2 main protease to prevent viral replication, while ritonavir boosts nirmatrelvir levels by inhibiting its metabolism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:44.462Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 (treatment of mild to moderate disease in adults at high risk of progression to severe disease)"}]},"trialDetails":[{"nctId":"NCT05041907","phase":"PHASE2","title":"Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2021-09-30","conditions":"COVID-19","enrollment":3800},{"nctId":"NCT04746183","phase":"PHASE1, PHASE2","title":"AGILE (Early Phase Platform Trial for COVID-19)","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2020-07-03","conditions":"Covid19","enrollment":600},{"nctId":"NCT06397144","phase":"PHASE1","title":"A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2025-08-15","conditions":"Biological Availability, Healthy Participants","enrollment":""},{"nctId":"NCT05386472","phase":"PHASE1","title":"A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-06-22","conditions":"COVID-19","enrollment":25},{"nctId":"NCT05261139","phase":"PHASE3","title":"EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-03-07","conditions":"COVID-19","enrollment":160},{"nctId":"NCT04960202","phase":"PHASE2, PHASE3","title":"EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-07-16","conditions":"COVID-19","enrollment":2091},{"nctId":"NCT05263895","phase":"PHASE1","title":"Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-03-03","conditions":"Bioavailability","enrollment":12},{"nctId":"NCT05668091","phase":"PHASE2","title":"A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.","status":"COMPLETED","sponsor":"Harlan M Krumholz","startDate":"2023-04-14","conditions":"Long COVID","enrollment":100},{"nctId":"NCT06441955","phase":"PHASE4","title":"Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.","status":"RECRUITING","sponsor":"Well- Konnect Healthcare Services and Research Firm","startDate":"2024-03-01","conditions":"COVID-19, Long Haul","enrollment":100},{"nctId":"NCT05898672","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-09","conditions":"Pharmacokinetics, Healthy Volunteers","enrollment":12},{"nctId":"NCT05339334","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-03-10","conditions":"Healthy Participants","enrollment":14},{"nctId":"NCT05567952","phase":"PHASE2","title":"A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-10-19","conditions":"COVID-19","enrollment":436},{"nctId":"NCT05487040","phase":"PHASE1","title":"A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-09-07","conditions":"COVID-19","enrollment":15},{"nctId":"NCT05438602","phase":"PHASE2","title":"A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-08-03","conditions":"COVID-19","enrollment":158},{"nctId":"NCT05525910","phase":"PHASE1","title":"Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-08-31","conditions":"Biological Availability, Healthy Participants","enrollment":15},{"nctId":"NCT05263921","phase":"PHASE1","title":"Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-03-10","conditions":"Bioavailability","enrollment":12},{"nctId":"NCT05544786","phase":"PHASE1","title":"Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-09-28","conditions":"Biological Availability","enrollment":12},{"nctId":"NCT05441215","phase":"PHASE1","title":"A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-12-12","conditions":"Healthy Participants","enrollment":8},{"nctId":"NCT05064800","phase":"PHASE1","title":"PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-09-21","conditions":"Healthy Participants","enrollment":24},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT04962230","phase":"PHASE1","title":"Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-07-15","conditions":"Healthy Participant","enrollment":12},{"nctId":"NCT05129475","phase":"PHASE1","title":"Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-11-12","conditions":"Healthy Participants","enrollment":12},{"nctId":"NCT05032950","phase":"PHASE1","title":"Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-09-17","conditions":"Healthy Participants","enrollment":12},{"nctId":"NCT05005312","phase":"PHASE1","title":"Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-31","conditions":"Hepatic Impairment","enrollment":17},{"nctId":"NCT05011513","phase":"PHASE2, PHASE3","title":"Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).","status":"TERMINATED","sponsor":"Pfizer","startDate":"2021-08-25","conditions":"COVID-19","enrollment":1440},{"nctId":"NCT04909853","phase":"PHASE1","title":"Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-06-15","conditions":"Renal Impairment","enrollment":35},{"nctId":"NCT04962022","phase":"PHASE1","title":"Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-07-20","conditions":"Healthy Participant","enrollment":12},{"nctId":"NCT05047601","phase":"PHASE2, PHASE3","title":"A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-09-09","conditions":"COVID-19","enrollment":2954},{"nctId":"NCT05545319","phase":"PHASE2","title":"A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2022-12-13","conditions":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised","enrollment":""},{"nctId":"NCT05366192","phase":"PHASE4","title":"The Safety of Paxlovid in Hemodialysis Patients With Covid-19","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2022-05-06","conditions":"Safety Issues","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["small dose"],"phase":"marketed","status":"active","brandName":"Nirmatrelvir and ritonavir stage 1","genericName":"Nirmatrelvir and ritonavir stage 1","companyName":"RenJi Hospital","companyId":"renji-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nirmatrelvir inhibits the SARS-CoV-2 main protease to prevent viral replication, while ritonavir boosts nirmatrelvir levels by inhibiting its metabolism. Used for COVID-19 (treatment of mild to moderate disease in adults at high risk of progression to severe disease).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}